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Abstract
Introduction: The aim of the study was to evaluate the concentration of 9a11b prostaglandin F2, a stable metabolite of
prostaglandin D2 (PGD2) and leukotriene E4 (LTE4), in patients with stable and exacerbated chronic obstructive pulmonary
disease (COPD).
Material and methods: The study included 29 COPD patients aged 73 ± 8.34 years, with mean FEV1 = 48.64 ± 15.75% of
predicted normal value, and 29 healthy controls aged 57.48 ± 10.86 years, with mean FEV1 = 97.17 ± 13.81% of predicted
normal value. Urine and blood samples were taken from COPD patients during exacerbation and in the stable phase of the
disease; LTE4 was measured in urine using commercial enzyme immunoassay (EIA), and 9a11b prostaglandin F2
(9a11bPGF2), a stable metabolite of PGD2, was measured in blood and urine using GC/MS.
Results: Urine concentrations of LTE4 in urine (677.15 vs. 436.4 pg/mg of creatinine; p = 0.035) and serum levels of
9a11bPGF2 (5.35 vs. 3.07 pg/ml; p = 0.007) were significantly higher in patients with exacerbated COPD than in the control
group. There was no difference in LTE4 levels in urine and 9a11bPGF2 in serum between exacerbated and stable COPD. The
urinary 9a11bPGF2 concentration did not differ between the studied groups. We found a positive correlation between
smoking history and urine LTE4 level (r = 0.395; p = 0.002) as well as blood 9a11bPGF2 concentration (r = 0.603; p =
0.001) in COPD patients.
Conclusions: Urine levels of 9a11bPGF2 and LTE4 did not differ between the stable COPD group and the control group. There
were no differences between urine LTE4 levels and blood and urine 9a11bPGF2 levels between exacerbated and stable
COPD. Finally, LTE4 concentration in urine and 9a11bPGF2 in blood were significantly higher in exacerbated COPD patients
than in the control group.
Key words: COPD, LTE4, PGD2, bronchoconstrictive eicosanoids
Pneumonol. Alergol. Pol. 2012; 80, 2: 120–126
Iwona Gross-Sondej et al., Measurement of bronchoconstrictive eicosanoids in chronic obstructive pulmonary disease
121www.pneumonologia.viamedica.pl
Introduction
Chronic obstructive pulmonary disease
(COPD) and bronchial asthma have a common de-
nominator of chronic inflammatory reaction in the
bronchial tree and lung parenchyma, resulting in
decreased bronchial air flow, which in COPD may
be partially irreversible [1–3].
Differences in cellular composition, underly-
ing mechanisms, distribution of lesions, and invo-
lved mediators in the course of remodelling of the
respiratory tract in respective diseases are well
known. These particularities are most pronounced,
for example, in non-smoking patients with mode-
rate asthma as compared to smoking COPD patients
with moderately advanced disease. The more ad-
vanced both diseases become, the less sharp is the
difference between them; therefore, separation
between these entities may seem only arbitrary.
Severe asthma with low reversibility of bron-
choconstriction after bronchodilator administra-
tion and resistance to systemic glucocorticoids is
marked by increased numbers of neutrophil gra-
nulocytes in bronchial mucosa samples and in
bronchioloalveolar lavage (BAL), with increased
proportion of CD8(+) lymphocytes observed in
autopsy samples [4–7]. In some COPD patients,
histological and cytological findings demonstrate
eosinophilia in sputum, BAL, and bronchial mu-
cosa samples. These inflammatory cells are cha-
racteristic for asthma, and their numbers increase
in COPD exacerbations, which coincides with in-
creasing levels of eosinophil cationic protein (ECP)
and increased expression of chemotactic factors [8–
10]. Bronchial mucosa samples from COPD pa-
tients also show mast cell infiltration, usually per-
ceived as hallmarks of allergic diseases. Mast cell
infiltration decreases under corticosteroid therapy,
which coincides with regression of symptoms [9].
The role of mast cells in the development of bron-
chial obturation is related to their enzymatic con-
stitution, as proteases (tryptase, chymase, elastase)
synthesized by mast cell damage to bronchial wall
components, inducing hyperreactivity and incre-
asing mucus secretion. On the other hand, mast cells
can synthesize and secrete the most potent broncho-
constrictors, including cysteinyl leukotrienes and
prostaglandin D2 [12–15]. Therefore, the impact of
eosinophils and mast cells, as well as their media-
tors, on the development of airway obturation in
COPD patients can be of great interest.
The aim of the study was to evaluate concentra-
tions of leukotriene E4 (LTE4) and 9a11bPGF2, a sta-
ble metabolite of prostaglandin D2, in patients with
COPD during stable disease and exacerbations.
Material and methods
The study group included 29 patients with
COPD (8 women, 21 men), aged 54–86 (mean age
73 ± 8.34) years. Mean value of forced expiratory
volume in one second (FEV1) was 1.22 ± 0.45 L in
stable disease (48.64 ± 15.75% of predicted nor-
mal value). In phases of disease exacerbation, FEV1
values were significantly lower compared to re-
adings from stable disease in the same patients (p
= 0.003). Eleven patients (37.93%) had moderate
disease, 15 patients had severe disease (51.72%),
and 3 persons suffered from a very severe form of
COPD (10.34%).
The control group included 29 persons (15
women, 14 men), aged 56–80 (mean age 57.48 ±
10.86) years. There were both non-smokers and
smoking persons in the control group, but none of
them had symptoms of COPD, asthma, or allergy.
All patients had normal serum IgE levels and num-
bers of blood eosinophils. Mean FEV1 value was
2.71 ± 0.61 l (97.17 ± 13.81% of predicted nor-
mal value). Exclusion criteria were signs of syste-
mic mastocytosis, unstable angina pectoris, or he-
art infarction as these entities are marked by strong
mast cell activation.
Patients with known COPD were qualified for
treatment within the first three days of exacerba-
tion, which was defined as suddenly increased
respiratory symptoms (dyspnoea, cough, increased
sputum production) as compared to each patient’s
stable state, with necessity of treatment modifica-
tion in an outpatient clinic or in hospital condi-
tions. Diagnosis and classification of COPD exacer-
bation was based on the criteria described by An-
thonisen et al. [16]. Three categories of exacerba-
tion were assigned, depending on the number and
type of observed symptoms: mild, moderate, and
severe. On inclusion, spirometry was performed
and FEV1 was used as a denominator of exacerba-
tion severity. Furthermore, blood and urine sam-
ples were collected for evaluation of serum and
urine 9a11bPGF2 levels by gas chromatography/
mass spectrometry (GC/MS; Hewlett Packard, Pa-
olo Alto, USA); urine LTE4 levels by enzyme-lin-
ked immunosorbent assay (ELISA; Cayman Che-
micals, AnnArbor, USA); absolute blood eosino-
phil count by microscopy using a Burker chamber;
and total serum IgE content by nephelometry (Dade
Behring, Newark, USA). Samples were collected
before onset of therapy for COPD exacerbation.
Before exacerbation, COPD patients were treated
with long acting beta2-adrenoreceptor blockers;
48.28% of patients received inhaled steroids, and
41.38% of persons had systemic steroids with a
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mean dose of 5.55 mg calculated for methylpred-
nisolone dose.
When a stable state was reached, approxima-
tely 2 months after exacerbation, spirometry was
performed again for evaluation of disease severi-
ty, and biochemical tests were again performed. All
patients with stable disease were treated with long-
acting beta2-adrenoreceptor blockers; 65.52% of pa-
tients received inhaled steroids, and 27.59% of per-
sons took oral steroids, with a mean dose of 4.7 mg
calculated for methylprednisolone dose (table 1).
In the control group, spirometry was perfor-
med once, followed by urine and serum marker
measurement as described above.
Results
Analysis of urine samples from COPD patients
showed significantly higher levels of LTE4 in exa-
cerbation phase as compared to healthy controls
(677.15 vs. 436.3 pg/mg creatinine; p = 0.035).
In stable COPD phase, urine LTE4 levels were
insignificantly lower as compared to exacerbation
readings, but these were at the same time higher
than in healthy subjects (table 2).
Serum levels of 9a11bPGF2 in patients with
exacerbated COPD were significantly higher than
in the control group (5.35 vs. 3.07 pg/ml; p = 0.007).
The level of the analysed PGD2 metabolite was
higher under COPD exacerbation than in stable
disease. Differences between 9a11bPGF2 readings
in these two disease stages were almost significant
(5.35 vs. 3.81 pg/ml; p = 0.068). Mean serum con-
centration of 9a11bPGF2 in COPD stable patients
and in healthy controls did not differ significantly
(3.81 vs. 3.07 pg/ml; p > 0.05) (table 3).
There were no significant differences betwe-
en mean urine PGD2 metabolite levels in exacer-
bated and stable COPD (0.46 vs. 0.44 ng/mg cre-
atinine; p >0.05). Mean urine levels of 9a11bPGF2
in COPD patients, both with exacerbated and sta-
ble disease, were not significantly different from
values found in healthy subjects (0.46 vs. 0.57 ng/
mg creatinine; p > 0.05 and 0.44 vs. 0.57 ng/mg
creatinine; p > 0.05) (table 4).
Correlation was found between smoking ha-
bit (measured in pack-years) and urine LTE4 levels,
both in stable COPD (r = 0.574; p = 0.002) and in
exacerbated disease (r = 0.395; p = 0.041), as well
as between smoking habit and serum 9a11bPGF2
level in exacerbated COPD (r = 0.603; p = 0.001).
Discussion
Current research on the mechanisms under-
lying allergic diseases, including bronchial asth-
ma, focuses on mast cells and mediators secreted
by them, including prostaglandin D2 and cysteinyl
leukotrienes. The role of these cells is also inve-
stigated in COPD. Histopathological pictures of
bronchial mucosa samples from patients with chro-
nic bronchitis reveal an increased population of
mast cells within the surface epithelium and in
submucosal glands [17]. Lung tissue from tobacco
Table 1. Characteristics of the study group and control group
Study group Control group
Number of patients n 29 29
Age (years) n ± SD 71.38 ± 8.34 57.48 ± 10.86
Women n (%) 8 (27.59) 15 (51.72)
FEV1 (L) n ± SD 1.22 ± 0.45 2.71± 0.61
FEV1 (%) n ± SD 48.64 ± 15.75 97.17 ± 13.81
FVC (L) n ± SD 2.27 ± 0.71 3.47 ± 0.73
FVC (%) n ± SD 70.74 ± 15.72 102.3 ± 15.10
Smokers n (%) 29 (100) 22 (75.86)
Current smokers n (%) 20 (68.97) 9 (31.03)
Ex-smokers n (%) 9 (31.03) 13 (44.83)
IgE [IU/ml] n ± SD 66.32 ± 70.03 47.92 ± 32.49
Eosinophils [n/ìl] n ± SD 232 ± 169 188.45 ± 106.09
Systemic steroid therapy (GCS) n (%) 12 (41.38)/8 (27.59) 0 (0)
Inhaled steroids n (%) 14 (48.28)/19 (65.52) 0 (0)
FEV1 = forced expiratory volume in one second; GCS = glucocorticoids; IgE = immunoglobulin E; SD = standard deviation
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smokers in resection specimens due to cancer
shows the presence of mast cells in the epithelium
of small bronchi [18]. The role of mast cells in
COPD pathogenesis may also be implied when
observing effects of inhaled steroids on the frequ-
ency of disease exacerbations. Giżycki et al. treated
their patient for 3 months with 1000 ìg fluticasone
propionate, and afterwards observed significantly
decreased numbers of mucosal mast cells in COPD
patients, with clinical findings of reduced cough
intensity, decreased amount of produced sputum,
and fewer exacerbation episodes [11].
Prostaglandin D2 is currently viewed as the
most sensitive and specific marker of inflammato-
ry reaction with a mastocytic component. Serum
and urine levels of 9a11bPGF2, a stable metaboli-
te of PGD2, have been measured in patients under
COPD exacerbation and stable disease. Significan-
tly higher concentrations of 9a11bPGF2 were fo-
und in serum under exacerbation as compared to
those found in the control group. The differences
between 9a11bPGF2 levels in exacerbated and sta-
ble COPD were, however, insignificant (p = 0.068),
which may be explained by the low number of
patients. Serum levels of PGD2 metabolite in control
subjects and stable COPD were not different, and
neither were urine levels of the same substance.
Few reports concerning PGD2 or its metaboli-
tes have been published until now; therefore, the-
re is only sparse data to compare with. Montuschi
et al. found similar levels of PGD2 metabolite,
metoxyPGD2, in exhaled air in COPD patients and
healthy controls [19]. Of note, prostaglandin levels
could be measured in only half of the studied persons.
In the presented study, significantly higher
LTE4 levels in urine were observed in exacerba-
ted COPD patients as compared to healthy persons,
but no such differences could be noted between
COPD in stable and exacerbated phase. These fin-
dings are in accordance with the results published
by Micheletto et al., who compared urine LTE4
concentrations in stable COPD and exacerbated
disease, in healthy controls and in patients with
mild atopic asthma [20]. Leukotriene synthesis in
COPD exacerbation and stable phase was assessed
in two groups of patients independently, which
differentiates the cited report from our study. The
authors observed significantly higher levels of uri-
ne LTE4 in exacerbated COPD and mild asthma
when compared to the control group. There were
no major differences in LTE4 levels between heal-
thy subjects and patients with stable COPD nor
between COPD patients with stable or exacerba-
ted disease. Of note, mean LTE4 levels during
COPD exacerbations were similar to the levels ob-
served in patients with mild asthma and history
of atopic disease.
A lack of significant differences in LTE4 syn-
thesis between COPD patients and healthy controls
was also described by Mierzejewska et al., who
Table 3. Serum 9a11bPGF2 concentration during exacerbation of chronic obstructive pulmonary disease (COPD), in stable
COPD and in healthy controls
9a11bPGF2 COPD exacerbation Stable COPD Control group Exacerbated p Stable vs.
[pg/ml] n = 27 n = 29 n = 29 vs. stable Exacerbated control group
 vs. stable
Mean ± SD 5.35 ± 5.35 3.81 ± 1.99 3.07 ± 1.05 0.068 0.007 0.225
Median 3.6 3.1 2.9
Min & max (1.2–30.2) (1.0–9.5) (1.2–5,6)
SD = standard deviation
Table 2. Leukotriene E4 (LTE4) concentrations in urine during exacerbation of chronic obstructive pulmonary disease
(COPD) in stable COPD and in healthy controls
LTE4 COPD exacerbation Stable COPD Control group Exacerbated p Stable vs.
[pg/mg creatinine] n = 27 n = 29 n = 29 vs. stable Exacerbated control group
 vs. stable
Mean ± SD 677.15 ± 543 613.31 ± 719 436.3 ± 243 0.62 0.035 0.70
Median 559 373 400
Min & max (103–2,646) (56–3,802) (93–1117)
SD = standard deviation
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analysed both urine samples and exhaled air [21].
Shindo et al. found, however, significantly higher
serum LTE4 levels under COPD exacerbation when
compared to stable disease [22]. These findings
differ from the conclusions of the presented study
but can possibly be explained by different measu-
rement techniques and examination of serum, and
not urine samples. In the cited report, LTE4 levels
in stable disease were similar to those found in
healthy patients.
When coparing the presented results with tho-
se from another study from the same centre, it sho-
uld be noted that urine LTE4 levels were similar
in our group and in patients with stable allergic
asthma, investigated by Bochenek et al., who ana-
lysed urine samples in stable disease and after al-
lergen provocation [23]. Baseline urine LTE4 levels
in asthmatic patients were similar to the ones we
found in patients with exacerbated COPD. Howe-
ver, these levels increased by almost 2.5 times after
allergen provocation (which is a supposed coun-
terpart of disease exacerbation), reaching levels not
noted in COPD.
In the presented study, a correlation was fo-
und between the number of smoked cigarettes
(expressed in pack-years) and urine LTE4 levels,
both in stable and exacerbated COPD. This finding
indirectly supports data from literature concerning
cell composition in the bronchial tree in smokers.
Amin et al. observed significantly higher numbers
of mast cells and eosinophils in mucosal samples
from asymptomatic smokers when compared to
non-smoking persons. Both of these cell types play
a major role in synthesis of cysteinyl leukotrienes
[24]. Moreover, increased expression of tenascin
and laminin as well as discontinuity of respirato-
ry epithelium could be found microscopically.
Furthermore, lung parenchyma in specimens re-
sected from smokers diagnosed with cancer sho-
wed the presence of mast cells in the epithelium
of small bronchi, which suggests a relationship
between mast cell infiltration and smoking, and
thus also in COPD development [25].
Increased LTE4 synthesis in COPD exacerba-
tion seems to correlate with increased inflamma-
tion, although not equally marked in asthma exa-
cerbation. Escalating intensity of inflammatory
reaction results in increased local influx of neu-
trophils, macrophages, and eosinophils as well as
in activation of intramural mast cells.
When comparing levels of LTE4 and
9a11bPGF2 in exacerbated COPD and after aller-
gen provocation in asthmatic patients, the role of
these eicosanoids in developing bronchial obtura-
tion in COPD patients seems secondary. Some au-
thors suggested administration of cysLT1receptor
antagonists or cysteinyl leukotriene synthesis bloc-
kers in both stable and exacerbated COPD, but this
seems insufficiently grounded. On the other hand,
the presented study includes measurements of sys-
temic levels of mediators, which are in fact syn-
thesized and exert their action locally (in the re-
spiratory tract). Further studies on bronchospastic
eicosanoids, with analysis of their levels in situ,
in lung parenchyma, and bronchial epithelium as
well as in bronchioloalveolar lavage and induced
sputum samples, can verify these observations.
Conclusions
Urine levels of LTE4 and 9a11bPGF2 in pa-
tients with exacerbated COPD do not significantly
differ from concentrations found in healthy sub-
jects. The mean concentrations of these eicosano-
ids in urine and levels of 9a11bPGF2 in serum
during COPD exacerbation are similar to those fo-
und in stable disease. Patients with disease exa-
cerbation had significantly increased urine LTE4
and serum 9a11bPGF2 levels when compared to
healthy persons. These parameters also correlate
with the number of cigarettes smoked by COPD
patients.
The presented results suggest that eicosano-
ids play a minor role in the pathogenesis of bron-
chial obturation and COPD exacerbation, and the-
ir increasing levels in exacerbation periods reflect
Table 4. Urine 9a11bPGF2 concentration during exacerbation of chronic obstructive pulmonary disease (COPD), in stable
COPD and in healthy controls
9a11bPGF2 COPD exacerbation Stable COPD Control group Exacerbated p Stable vs.
[pg/ml] n = 27 n = 29 n = 29  vs. stable Exacerbated control
vs. stable group
Mean ± SD 0.49 ± 0.27 0.50 ± 0.35 0.62 ± 0.37 0.844 0.181 0.113
Median 0.46 0.44 0.57
Min & max (0.1–1.12) (0.13–1.59) (0.07–1.56)
SD = standard deviationa
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induced inflammatory reaction, with increased
influx of inflammatory cells to bronchial mucosa
and lung parenchyma.
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